Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05004025 · ClinicalTrials.gov registry record · Phase 1
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
A Phase 1 study, sponsored by HonorHealth Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05004025 is a Phase 1 study that has completed, run by HonorHealth Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT05004025, a Phase 1 study, has completed, sponsored by HonorHealth Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.
Interventions
- DRUG Yervoy
- DEVICE Novocure Optune
- DRUG Opdivo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-02-28 |
| Est. Completion | 2025-07-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05004025
The ClinicalTrials.gov registry entry for NCT05004025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Yervoy is the first listed.
NCT05004025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05004025 about?
NCT05004025 is a clinical study titled "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma". Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.
What is the current status of trial NCT05004025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-02-28. Estimated completion is 2025-07-23.
What interventions are being tested in trial NCT05004025?
The interventions under investigation include: Yervoy (DRUG), Novocure Optune (DEVICE), Opdivo (DRUG).
Who is sponsoring clinical trial NCT05004025?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.